Iceland· IS-EU/1/24/1841/001-002 & EU/1/24/1841/003-004
Balversa
A erdafitinib product containing erdafitinib, registered in Iceland by Janssen-Cilag International NV*. The same ATC class is registered in 14 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Erdafitinib is registered in 14 of 19 countries.
Countries holding a registration under ATC L01EN01 (erdafitinib), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 8 of them publish a price we can compare per daily dose
Erdafitinib · ATC L01EN01
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of erdafitinib costs, country by country.
Normalised to the WHO defined daily dose (9 mg), the median price runs from $0.55 in France to $621.10 in Switzerland — a ×1128 gap.
- 2 markets with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Erdafitinib · price per daily dose (9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$621.10
- FR France$0.55
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- Erdafitinib
- Manufacturer
- Janssen-Cilag International NV*
- Country
- Iceland (IS)
- ATC code
- L01EN01
- ATC class
- Erdafitinib
- Defined daily dose
- 9 mg, O
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 1
1 priced- ean41513084 stk x1 glasISK 1440574
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
154 interactions on record for erdafitinib.
Graded by severity as the source publishes them — 56 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Erdafitinib · interactions on record
154 records
- 56 severe
- 98 moderate
Most severe, free to view
- Magnesium carbonateA02AA01severe
- Magnesium oxideA02AA02severe
- Magnesium hydroxideA02AA04severe
- Kombinationen von AluminiumsalzenA02AB10severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Erdafitinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaBALVERSAJanssen-Cilag International N.V., Beerse
- SwitzerlandBalversa
- FinlandBalversaJanssen Cilag International
- FranceBALVERSA 3 mg, comprimés pelliculésJANSSEN CILAG INTERNATIONAL NV
- IrelandBalversa 3 mg Film-coated tabletJanssen-Cilag International NV
- NetherlandsBalversa 3 mg filmomhulde tablettenJanssen-Cilag International NV
- NorwayBalversaJanssen-Cilag International N.V.
- PolandBalversaJanssen-Cilag International N.V.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Balversa
- Norway · Balversa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/e481b951-d9f4-46b6-b572-c51465f70dcf GET /v1/drugs/e481b951-d9f4-46b6-b572-c51465f70dcf?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Filmuhúðuð tafla",
"source": "lyfjastofnun",
"atc_raw": "L01EN01",
"marketed": true,
"strength": "3 mg",
"ma_number": "EU/1/24/1841/001-002 & EU/1/24/1841/003-004",
"substance": "Erdafitinib",
"other_info": "Ávísun lyfsins er bundin við sérfræðinga í krabbameinslækningum.",
"legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
"ma_issued_serial": "45526"
}See everything about erdafitinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.